Madhusudan Grover, M.B.B.S.

The purpose of this of this study is to develop a de novo CIPO-specific PRO (chronic intestinal pseudo obstruction) (patient recorded outcomes) that is able to capture change in core CIPO visible signs and symptoms across all etiologies and severity levels, and is fit-for-purpose for use as a primary endpoint in a clinical trial setting.

The purpose of this study is to learn the efficacy and safety of fecal microbiota transplantation (FMT) using stool from a donor with low proteolytic activity and containing the bacteria Alistipes putredinis in patients with post-infection irritable bowel syndrome (PI-IBS) and high proteolytic activity. Proteolytic activity is the breakdown of proteins into smaller polypeptides or amino acids.

Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS). The researchers are doing this study to understand if changes in gut bacteria and gut mucosal lining during an acute infection can help identify individuals who might be at risk for developing problems in the future.

The purpose of this this Rome foundation biOmarker and phenotyping projecT  is to develop a state-of-the-art clinical database and biobank of patients with DGBI.

The purpose of this study is to assess the effectiveness of AZ-010 as an acute treatment for moderate to severe cyclic vomiting syndrome (CVS) in adult patients, and the safety of AZ-010 in adult patients with moderate-to-severe cyclic vomiting syndrome (CVS).

A study of the efficacy and safety of Lubiprostone in subjects diagnosed with IBS-M/IBS-U.

Our overall objective with this study is firstly to provide a comprehensive assessment of intestinal permeability, mucosal barrier function using existing biomarkers and secondly to explore novel biomarkers for measuring intestinal permeability in patients with constipation predominant Irritable Bowel Syndrome (IBS-C).

This study is to evaluate the effectiveness of the investigational drug motilitone at 90 mg in patients with functional dyspepsia as measured by change in maximum tolerated volume and the aggregate symptom score on the nutrient drink test.

The purpose of this study is to demonstrate feasibility of dynamic 11C-ER176 PET imaging to identify macrophage-driven immune dysregulation in gastric muscle of patients with DG. Non-invasive quantitative assessment with PET can significantly add to our diagnostic armamentarium for patients with diabetic gastroenteropathy.

Some people develop chronic abdominal pain with diarrhea or constipation after an episode of acute bacterial gastroenteritis. These symptoms can be consistent with post-infectious irritable bowel syndrome (IBS) and can last long after the acute infection is over. The exact reason why certain individuals develop these symptoms whereas others don't is not exactly clear. The researchers are studying changes in gastrointestinal permeability (movement of contents across the lining of the intestine) and transit (movement of food through the gastrointestinal tract). The researchers are also studying if there are any genetic risk factors that are associated with development of this disorder.

To better understand the relationship between gut barrier function and the symptomatology and pathophysiology of IBS.

The purpose of this study is to identify twin pairs where one or both the siblings have Irritable bowel syndrome (IBS) based on the Rome III criteria and to determine fecal microbiota changes in concordant and discordant twins with IBS.

The investigators' overall objective with this study is to determine performance characteristics of small intestine permeability measurement using 13C mannitol and 12C (regular) mannitol.

The purpose of this study is to determine differences in microbiota composition in volunteers with and without Rome IV defined Campylobacter jejuni PI-IBS, and to determine differences in peripheral metabolites, proteins and lipids in volunteers with and without Rome IV defined Campylobacter jejuni PI-IBS.